1. Home
  2. ACRS vs IMA Comparison

ACRS vs IMA Comparison

Compare ACRS & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • IMA
  • Stock Information
  • Founded
  • ACRS 2012
  • IMA 2019
  • Country
  • ACRS United States
  • IMA United States
  • Employees
  • ACRS N/A
  • IMA N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • IMA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ACRS Health Care
  • IMA Health Care
  • Exchange
  • ACRS Nasdaq
  • IMA Nasdaq
  • Market Cap
  • ACRS 165.7M
  • IMA 159.1M
  • IPO Year
  • ACRS 2015
  • IMA N/A
  • Fundamental
  • Price
  • ACRS $1.95
  • IMA $9.14
  • Analyst Decision
  • ACRS Strong Buy
  • IMA
  • Analyst Count
  • ACRS 9
  • IMA 0
  • Target Price
  • ACRS $9.25
  • IMA N/A
  • AVG Volume (30 Days)
  • ACRS 891.2K
  • IMA 42.6K
  • Earning Date
  • ACRS 11-05-2025
  • IMA 01-01-0001
  • Dividend Yield
  • ACRS N/A
  • IMA N/A
  • EPS Growth
  • ACRS N/A
  • IMA N/A
  • EPS
  • ACRS N/A
  • IMA N/A
  • Revenue
  • ACRS $16,789,000.00
  • IMA $4,300,000.00
  • Revenue This Year
  • ACRS N/A
  • IMA N/A
  • Revenue Next Year
  • ACRS N/A
  • IMA N/A
  • P/E Ratio
  • ACRS N/A
  • IMA N/A
  • Revenue Growth
  • ACRS N/A
  • IMA N/A
  • 52 Week Low
  • ACRS $1.05
  • IMA $7.95
  • 52 Week High
  • ACRS $5.17
  • IMA $23.28
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 56.76
  • IMA N/A
  • Support Level
  • ACRS $2.01
  • IMA N/A
  • Resistance Level
  • ACRS $2.16
  • IMA N/A
  • Average True Range (ATR)
  • ACRS 0.10
  • IMA 0.00
  • MACD
  • ACRS -0.01
  • IMA 0.00
  • Stochastic Oscillator
  • ACRS 47.44
  • IMA 0.00

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About IMA ImageneBio Inc. Common Stock

ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.

Share on Social Networks: